Abstract
708 Side effects of BCG in the treatment of intermediate and high risk Ta T1 papillary carcinoma of the bladder: Results from EORTC GU Cancers Group randomized study 30962 comparing 1/3 dose vs full dose during 1 or 3 years
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have